Literature DB >> 28215783

Synthesis and biological evaluation of potential inhibitors of the cysteine proteases cruzain and rhodesain designed by molecular simplification.

Saulo Fehelberg Pinto Braga1, Luan Carvalho Martins1, Elany Barbosa da Silva2, Policarpo Ademar Sales Júnior3, Silvane Maria Fonseca Murta3, Alvaro José Romanha3, Wai Tuck Soh4, Hans Brandstetter4, Rafaela Salgado Ferreira2, Renata Barbosa de Oliveira5.   

Abstract

Analogues of 8-chloro-N-(3-morpholinopropyl)-5H-pyrimido[5,4-b]indol-4-amine 1, a known cruzain inhibitor, were synthesized using a molecular simplification strategy. Five series of analogues were obtained: indole, pyrimidine, quinoline, aniline and pyrrole derivatives. The activity of the compounds was evaluated against the enzymes cruzain and rhodesain as well as against Trypanosoma cruzi amastigote and trypomastigote forms. The 4-aminoquinoline derivatives showed promising activity against both enzymes, with IC50 values ranging from 15 to 125µM. These derivatives were selective inhibitors for the parasitic proteases, being unable to inhibit mammalian cathepsins B and S. The most active compound against cruzain (compound 5a; IC50=15µM) is considerably more synthetically accessible than 1, while retaining its ligand efficiency. As observed for the original lead, compound 5a was shown to be a competitive enzyme inhibitor. In addition, it was also active against T. cruzi (IC50=67.7µM). Interestingly, the pyrimidine derivative 4b, although inactive in enzymatic assays, was highly active against T. cruzi (IC50=3.1µM) with remarkable selectivity index (SI=128) compared to uninfected fibroblasts. Both 5a and 4b exhibit drug-like physicochemical properties and are predicted to have a favorable ADME profile, therefore having great potential as candidates for lead optimization in the search for new drugs to treat Chagas disease.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  4-Aminopyrimides; 4-Aminoquinolines; Chagas disease; Cruzain; Molecular simplification; Rhodesain

Mesh:

Substances:

Year:  2017        PMID: 28215783     DOI: 10.1016/j.bmc.2017.02.009

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  6 in total

1.  Benzimidazole inhibitors of the major cysteine protease of Trypanosoma brucei.

Authors:  Glaécia An Pereira; Lucianna H Santos; Steven C Wang; Luan C Martins; Filipe S Villela; Weiting Liao; Marco A Dessoy; Luiz C Dias; Adriano D Andricopulo; Mariana Af Costa; Ronaldo Ap Nagem; Conor R Caffrey; Klaus R Liedl; Ernesto R Caffarena; Rafaela S Ferreira
Journal:  Future Med Chem       Date:  2019-07       Impact factor: 3.808

2.  Investigation of the binding mode of a novel cruzain inhibitor by docking, molecular dynamics, ab initio and MM/PBSA calculations.

Authors:  Luan Carvalho Martins; Pedro Henrique Monteiro Torres; Renata Barbosa de Oliveira; Pedro Geraldo Pascutti; Elio A Cino; Rafaela Salgado Ferreira
Journal:  J Comput Aided Mol Des       Date:  2018-03-21       Impact factor: 3.686

3.  Development of a pharmacophore for cruzain using oxadiazoles as virtual molecular probes: quantitative structure-activity relationship studies.

Authors:  Anacleto S de Souza; Marcelo T de Oliveira; Adriano D Andricopulo
Journal:  J Comput Aided Mol Des       Date:  2017-08-09       Impact factor: 3.686

4.  Chagas Disease Treatment and Rational Drug Discovery: A Challenge That Remains.

Authors:  Ana Catarina Cristovão Silva; Maria Carolina Accioly Brelaz-de-Castro; Ana Cristina Lima Leite; Valéria Rêgo Alves Pereira; Marcelo Zaldini Hernandes
Journal:  Front Pharmacol       Date:  2019-08-02       Impact factor: 5.810

Review 5.  Structural simplification: an efficient strategy in lead optimization.

Authors:  Shengzheng Wang; Guoqiang Dong; Chunquan Sheng
Journal:  Acta Pharm Sin B       Date:  2019-06-06       Impact factor: 11.413

6.  New Amino Naphthoquinone Derivatives as Anti-Trypanosoma cruzi Agents Targeting Trypanothione Reductase.

Authors:  Christian Espinosa-Bustos; Mariana Ortiz Pérez; Alonzo Gonzalez-Gonzalez; Ana María Zarate; Gildardo Rivera; Javier A Belmont-Díaz; Emma Saavedra; Mauricio A Cuellar; Karina Vázquez; Cristian O Salas
Journal:  Pharmaceutics       Date:  2022-05-25       Impact factor: 6.525

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.